6533b82efe1ef96bd129460a
RESEARCH PRODUCT
Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis.
Kaspar BerneisRizzo ManfrediZeynep OzbalkanGiatgen A. SpinasGiovam Battista RiniMustafa Cesursubject
medicine.medical_specialtyCholesterolbusiness.industry10265 Clinic for Endocrinology and DiabetologyArthritisBlood lipids610 Medicine & healthRheumatoid arthritis small dense LDL HDL-cholesterol Triglyceridesmedicine.disease2705 Cardiology and Cardiovascular MedicineRheumatologychemistry.chemical_compoundHigh-density lipoproteinEndocrinologychemistryInternal medicineRheumatoid arthritisLow-density lipoproteinmedicineCardiology and Cardiovascular MedicinebusinessaterosclerosiDyslipidemiadescription
Abstract Objective : Subjects with rheumatoid arthritis (RA) have increased cardiovascular risk and may show atherogenic forms of dyslipidemia. The present study investigated whether patients with early RA, beyond alterations in plasma lipids, also show lower LDL size and altered LDL subclass distribution. Design and Methods We identified 25 subjects with RA (47±8 years, body mass index (BMI) 25±4kg/m 2 ) by the American College of Rheumatology diagnostic criteria, with a disease durations Results As compared to controls RA patients had higher plasma triglycerides (1.8±0.5 vs. 1.0±0.5mmol/L, p p =0.0027), while total- and LDL-cholesterol concentrations were similar. LDL particle size was lower in RA patients than controls (264±7 vs. 281±9A, p p =0.0004) and LDL-IIA (14±3 vs. 16±3%, p =0.0182), and more LDL-IIIB (7±1 vs. 5±1%), -IVA (11±2 vs. 8±2%) and -IVB particles (12±2 vs. 9±2%,) ( p Conclusions Beyond plasma lipids, increased levels of small, dense LDL seems to be common in drug-naive patients with early RA. Yet, whether these findings affect the atherogenic process and the clinical endpoints in these subjects remains to be determined by future prospective studies.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2009-12-01 |